{"task_id": "c6248a79b6e4c21a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 199/464)", "text": "ld be considered\nSTAGING (CONT\u2019D)\n188\nMesothelioma\n\n--- Page 210 ---\nThymoma and Thymic Carcinoma\nPATHOPHYSIOLOGY\nCLASSIFICATION BY HISTOLOGY\n\u0002\nEPITHELIAL\n\u0002\nNEUROENDOCRINE\n\u0002\nGERM CELL\n\u0002\nLYMPHOID\n\u0002\nSTROMAL\nCLINICAL FEATURES\nLOCOREGIONAL\ndyspnea, cough, chest pain, hoar\nseness, dysphagia, superior vena cava obstruction\nMETASTATIC\nCONSTITUTIONAL\nweight loss, anorexia, fatigue\nPARANEOPLASTIC\nmyasthenia gravis (30 50%,\ndiplopia, ptosis, dysphagia, weakness, fatigue),\npure red cell aplasia (5 15%), pure white cell apla\nsia,\npancytopenia,\nhypogammaglobulinemia\n(recurrent infections, diarrhea), rheumatologic dis\neases, and endocrinopathies. Note that remission of\nthymoma does not necessarily correlate with\nimprovement of paraneoplastic syndromes\nSTAGING\nYAMAKAWA MASAOKA TNM STAGING\nT stage\n\u0002 T1=intact capsule\n\u0002 T2=macroscopically invades surrounding fatty\ntissue or mediastinal pleura, microscopically\ninvades capsule\n\u0002 T3=invades pericardium, great vessels, lung\n\u0002 T4=pleural or pericardial dissemination\nN stage\n\u0002 N1=anterior mediastinal LN\n\u0002 N2=other intrathoracic LN\n\u0002 N3=extrathoracic LN\nM stage (drop metastasis in pleural space)\n\u0002 M1=distant metastasis\nSTAGE GROUPINGS\nStage TNM @=any\n5 year survival\nI\nT1N0M0\n95%\nII\nT2N0M0\n85%\nIII\nT3N0M0\n70%\nIVA\nIVB\nT4N0M0\nT@N1 3M0, T@N@M1g 50%\nRelated Topic\nMyasthenia Gravis (p. 318)\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, glucose, AST, ALT,\nALP, bili\n\u0002\nIMAGING\nCXR, CT chest\n\u0002\nBIOPSY\nMANAGEMENT\nSTAGE I, II, III (resectable disease)\nresection\n(usually including adjacent lung\nparenchyma\nand pericardium) \u0006 adjuvant radiation \u0006 (neo)\nadjuvant\nchemotherapy\n(cisplatin etoposide,\ncisplatin doxorubicin cyclophosphamide)\nSTAGE IV (unresectable disease)\npalliative radia\ntion \u0006 palliative chemotherapy (cisplatin etopo\nside, cisplatin doxorubicin cyclophosphamide)\nTREATMENT ISSUES\nINDICATIONS FOR RADIOTHERAPY\nlocally ad\nvanced or metastatic unresectable disease, residual\ndisease post resection, and complete resection of\ninvasive thymoma or thymic carcinoma\nBreast Cancer\nNEJM 2004 350:14\nDIFFERENTIAL DIAGNOSIS OF BREAST MASS\nBENIGN\ncysts (obstructed collecting ducts), fibroa\ndenoma (overgrowth of periductal stromal connec\ntive tissue within the lobules), mammary duct\nectasia, intraductal papilloma, mastitis, fat necrosis\nATYPICAL HYPERPLASIA\n3 5\u0003 increased risk of\nbreast cancer\nCARCINOMA IN SITU\nductal (DCIS), lobular (LCIS)\nMALIGNANT\nbreast cancer (see below for details)\nPATHOPHYSIOLOGY\nCLASSIFICATION OF PRE MALIGNANT LESIONS\n\u0002\nDUCTAL CARCINOMA IN SITU (DCIS)\nprecursor lesion\nto invasive cancer\n\u0002\nLOBULAR CARCINOMA IN SITU (LCIS)\ndiffuse and can\nbe bilateral (risk of contralateral invasive breast\ncancer may be as high as ipsilateral disease). Marker\nfor increased risk of development of invasive cancer\n(1% 1 year of development of invasive cancer)\nSTAGING (CONT\u2019D)\nBreast Cancer\n189", "text_length": 2856, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 199/464)", "type": "chunk", "chunk_index": 198, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.519686", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.520469", "status": "complete", "chunks_added": 2}